AIDS therapies

Joseph EK, Chen X et al (2004) Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 107(1-2) 147-158 Jubelt B, Berger JR (2001) Does viral disease underlie ALS Lessons from the AIDS pandemic. Neurology 57(6) 945-946... 

AIDS therapy, as they inhibit the binding of HIV envelope protein gp-120 to human CD4 cells [105a]. 

Bourinbaiar AS, Jirathitikal V bow-cost anti-HIV compounds potential apphcation for AIDS therapy in developing countries. Curr Pharm Des 2003 ... 

Co-morbid factors that increase the risk of NSAID-induced GI bleeding include history of ulcer disease, advanced age, poor health status, treatment with certain drugs (discussed later), long duration of NS AID therapy, smoking, and heavy alcohol use. Because of their renal effects, NSAIDs must be used with caution in... 

Tipranavir, a VIH-PR inhibitor, was launched for AIDS therapy (Figure 8.12). Pleconaril inhibits adhesion by binding the viral capsid. It is currently being evaluated for viral infections of the respiratory tract, in particular, for picornavims (meningitis) and rhinovirus (colds) (Figure 8.12). 

Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990 249 1533-1544. 

Cohen, J. T Cell Shill Key rn AIDS Therapy. " Science. 175 [October 8. 1993) Cohen. I. and L.A. Segal Design Principles for the Immune System a ml Oilier Distributed Anumonumy Systems. Oxford Universuy Press, Ine, New York. NY. 2001... 

Perhaps psychopharmacological treatments for psychotic disorders in the future will need to borrow a chapter out of the book of cancer chemotherapy and HIV/ AIDS therapy, in which the standard of treatment is to use multiple drugs simultaneously to attain therapeutic synergy. Combination chemotherapy for malignancy uses the approach of adding together several independent therapeutic mechanisms. When successful, this results in a total therapeutic response that is greater than the sum of its parts. 

Tbmasselli AG, Heinrikson RL. Targeting the HIV-protease in AIDS therapy A current clinical perspective. Biochem Biophys Acta. 2000 1477 189-214. 

Minquartynoic acid 110 (Scheme 12.17) was isolated from the bark of Minquartia guianensis and represents a very promising lead compound for cancer and AIDS therapy [53]. 

Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism implication for HIV/ AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003 306 287-300. 

HIV/AIDS therapies. However, the development of raltegravir, the first member of an entirely new class of drugs that target a viral mechanism not previously exploited in the clinic, has provided physicians and patients a welcome addition to the HIV/AIDS treatment armamentarium. 

Twelve month studies may be more appropriate for chronically used drugs to be approved on the basis of short-term clinical trials employing efficacy surrogate markers where safety data from humans are limited to short-term exposure, such as some acquired immunodeficiency (AIDS) therapies. 

Figure 16.20. Peptide-derived TSA inhibitors used clinically in HIV protease-based AIDS therapies.

Example A study in 1,219 patients of the ATHENA (AIDS Therapy Evaluation National Centre) cohort of patients infected with HIV receiving antiretroviral therapy in the Netherlands showed a frequency of urological symptoms (including nephrolithiasis, renal colic, flank pain, hematuria, renal insufficiency, or nephropathy) of 8.3 per 100 treatment-years for indinavir compared to 0.8 per 100 treatment-years for other HIV protease inhibi-... 

Federal Register 57 (15 April 1992) 13250 Levi, Unproven AIDS Therapies. ... 

Levi, J. Unproven AIDS Therapies The Food and Drug Administration and ddl. In Biomedical Politics, ed. K. Hanna, 9-37. Washington, D.C. National Academy Press, 1991. 

---